Circulation

OCTOBER 20, 2024

Circulation, Volume 150, Issue 17 , Page 1313-1314, October 22, 2024.

Heart Transplant 45

Heart Transplant Transplant Circulation 45

Circulation

NOVEMBER 11, 2024

Circulation, Volume 150, Issue Suppl_1 , Page A4146828-A4146828, November 12, 2024. Heart transplantation remains a vital treatment for end-stage heart failure, yet the scarcity of suitable donor hearts makes the treatment unavailable to many patients in critical need.

Transplant 40

Transplant Heart Transplant Heart Dysfunction Heart Failure 40

Circulation

MARCH 30, 2025

Circulation, Volume 151, Issue 13 , Page 910-912, April 1, 2025.

Heart Transplant 49

Heart Transplant Transplant Circulation 49

Circulation

MARCH 11, 2024

Circulation, Ahead of Print. Hematopoietic stem cell transplantation can cure various disorders but poses cardiovascular risks, especially for elderly patients and those with cardiovascular diseases. Cardiovascular evaluations are crucial in pretransplantation assessments, but guidelines are lacking.

Transplant 45

Transplant Cardiovascular Disease Atrial Fibrillation Pediatrics 45

Circulation: Genomic and Precision Medicine

SEPTEMBER 28, 2023

Circulation: Genomic and Precision Medicine, Volume 16, Issue 5 , Page 452-461, October 1, 2023. Background:Many cardiovascular disorders propel the development of advanced heart failure that necessitates cardiac transplantation. of patients with unexplained end-stage cardiomyopathy.

Heart Transplant 40

Heart Transplant Transplant Cardiomyopathy Pediatrics 40

Circulation

NOVEMBER 11, 2024

Circulation, Volume 150, Issue Suppl_1 , Page A4123674-A4123674, November 12, 2024. Background:Transplantation arteriosclerosis is one of the major complications for the mid- and long-term survival of recipients with organ transplantation.

Transplant 40

Transplant Innovation Circulation 40

Circulation

NOVEMBER 11, 2024

Circulation, Volume 150, Issue Suppl_1 , Page A4146920-A4146920, November 12, 2024. Cox regression results showed that there is an increased risk of mortality in patients who did not receive transfusions before transplant (p<0.0001).Conclusion:While

Transplant 40

Transplant Heart Transplant Risk Factors Outcomes 40

Circulation

SEPTEMBER 10, 2024

Circulation, Ahead of Print. Early identification of kidney dysfunction in patients with advanced heart failure is crucial for timely interventions. Hemodynamic derangements and maladaptive neurohormonal upregulations contribute to fluctuations in kidney indices and electrolytes that may recover with guideline-directed medical therapy.

Heart Failure 80

Heart Failure Kidney Disease Heart Transplant Transplant 80

Journal of Clinical Investigation - Cardiology

JANUARY 16, 2024

Accurate detection of graft-versus-host disease (GVHD) is a major challenge in the management of patients undergoing hematopoietic stem cell transplantation (HCT). Here, we demonstrated the use of circulating cell-free DNA (cfDNA) for detection of tissue turnover and chronic GVHD (cGVHD) in specific organs. BACKGROUND. CONCLUSION.

Biomarkers 68

Biomarkers Transplant Circulation Research 68

Circulation

JANUARY 26, 2025

Circulation, Volume 151, Issue 4 , Page 309-311, January 28, 2025.

Transplant 45

Transplant Circulation 45

Circulation: Heart Failure

APRIL 14, 2025

Circulation: Heart Failure, Ahead of Print.

Cardiogenic Shock 40

Cardiogenic Shock Heart Failure Transplant Cardiomyopathy 40

Circulation

FEBRUARY 26, 2024

Circulation, Ahead of Print. Individual programs oftentimes develop upper age limits for various interventional strategies for their patients, including heart transplantation and durable left ventricular assist devices. Older adults have been largely excluded from analyses of therapeutic options in patients with cardiogenic shock.

Cardiogenic Shock 74

Cardiogenic Shock Best Practices Heart Transplant Transplant 74

Circulation: Heart Failure

AUGUST 1, 2024

Circulation: Heart Failure, Ahead of Print.

Heart Transplant 40

Heart Transplant Education Transplant Heart Failure 40

Circulation: Heart Failure

DECEMBER 11, 2023

Circulation: Heart Failure, Ahead of Print.

Heart Transplant 40

Heart Transplant Transplant Heart Failure Circulation 40

Circulation: Heart Failure

DECEMBER 9, 2024

Circulation: Heart Failure, Ahead of Print.

Heart Transplant 40

Heart Transplant Transplant Heart Failure Circulation 40

Frontiers in Cardiovascular Medicine

MARCH 5, 2024

Chronic kidney disease (CKD) significantly increases cardiovascular risk and mortality, and the accumulation of uremic toxins in the circulation upon kidney failure contributes to this increased risk.

Kidney Disease 59

Kidney Disease Transplant Circulation 59

Circulation: Cardiovascular Imaging

JANUARY 15, 2024

Circulation: Cardiovascular Imaging, Volume 17, Issue 1 , Page e016408, January 1, 2024.

Transplant 40

Transplant Cardiovascular Imaging Circulation 40

Circulation

FEBRUARY 12, 2024

Circulation, Ahead of Print. BACKGROUND:Much of our knowledge of organ rejection after transplantation is derived from rodent models.METHODS:We used single-nucleus RNA sequencing to investigate the inflammatory myocardial microenvironment in human pediatric cardiac allografts at different stages after transplantation.

Transplant 45

Transplant Pediatrics Circulation 45

Circulation: Cardiovascular Interventions

APRIL 14, 2025

Circulation: Cardiovascular Interventions, Volume 18, Issue 4 , Page e014919, April 1, 2025. CONCLUSIONS:In cardiac transplant recipients, IMR had superior repeatability compared with CFR and MRR derived from either bolus or continuous thermodilution, and was equally repeatable compared with RHyp. versus 0.70 versus 0.20 versus 0.87;P=0.188).

Physiology 40

Physiology Transplant Cardiovascular Interventions Circulation 40

Circulation

NOVEMBER 11, 2024

Circulation, Volume 150, Issue Suppl_1 , Page A4146823-A4146823, November 12, 2024. Heart transplant rates were low but increased slightly in 2020 for patients without CHD, with DV and SV CHD patients showing fluctuating rates peaking in 2018 and 2019, then declining in 2020. Patients without CHD were older (mean age 71.5

Cardiogenic Shock 40

Cardiogenic Shock Congenital Heart Disease Heart Failure Congenital 40

Circulation: Heart Failure

FEBRUARY 5, 2024

Circulation: Heart Failure, Ahead of Print. BACKGROUND:Cardiac allograft vasculopathy (CAV) is the leading cause of late graft dysfunction in heart transplantation. The 5-year risk (95% CI) of the International Society for Heart and Lung Transplantation–defined CAV in the high, moderate, low, and very low risk groups was 49.1% (35.2%–68.5%),

Heart Transplant 40

Heart Transplant Ultrasound Transplant Heart Failure 40

Circulation

NOVEMBER 11, 2024

Circulation, Volume 150, Issue Suppl_1 , Page A4113494-A4113494, November 12, 2024. End-stage ischemic heart disease necessitates heart transplantation, and emerging cell therapy presents a promising solution to address donor scarcity.

Ischemia 40

Ischemia Transplant Heart Transplant Biomarkers 40

Circulation

NOVEMBER 11, 2024

Circulation, Volume 150, Issue Suppl_1 , Page A4142247-A4142247, November 12, 2024. Background:Cardiac transplantation remains the single most effective treatment for end-stage heart failure. Autoradiography revealed68Ga-grazytracer accumulation in the transplanted heart. at POD 7 days; P<0.001).

Transplant 40

Transplant Heart Failure Circulation Outcomes 40

Circulation

DECEMBER 17, 2024

Circulation, Ahead of Print. We explored the mechanism of METTL4 involvement in atherosclerosis usingMettl4Mac-KO-Apoe-/-andMettl4MUT-Apoe-/-mice and cell models, as well as bone marrow transplantation. BACKGROUND:Mitochondrial dysfunction is a key factor in the development of atherogenesis.

Atherosclerosis 40

Atherosclerosis Transplant Plaque Pharmacology 40

Circulation

NOVEMBER 11, 2024

Circulation, Volume 150, Issue Suppl_1 , Page A4145296-A4145296, November 12, 2024. Aortic valve stenosis (AS) is often a contraindication to liver transplantation (LT). Aortic valve peak velocity (AVVmax) increased steadily as patients neared transplant and dropped significantly immediately after transplantation (Figure 1A).

Aortic valve 40

Aortic valve Aortic Transplant Stenosis 40

Circulation

NOVEMBER 11, 2024

Circulation, Volume 150, Issue Suppl_1 , Page A4144461-A4144461, November 12, 2024. Introduction:Left ventricular assist devices (LVADs) have become an increasingly common treatment option for patients with advanced heart failure, serving as either a bridge to transplantation or destination therapy.

Transplant 40

Transplant Risk Factors Heart Failure Circulation 40

Circulation: Heart Failure

FEBRUARY 13, 2024

Circulation: Heart Failure, Ahead of Print. BACKGROUND:Cardiac allograft rejection is the leading cause of early graft failure and is a major focus of postheart transplant patient care.

Transplant 40

Transplant Heart Failure Patient Care Circulation 40

Circulation

NOVEMBER 11, 2024

Circulation, Volume 150, Issue Suppl_1 , Page A4134590-A4134590, November 12, 2024. The association between a lower rate of MAE and EMB persisted in the multivariate model when those with heart transplant who had EMB were compared to those without heart transplant who did not have EMB p=0.001.

Cardiomyopathy 40

Cardiomyopathy Pediatrics Heart Transplant Heart Failure 40

Circulation: Heart Failure

JANUARY 16, 2025

Circulation: Heart Failure, Ahead of Print. BACKGROUND:Right ventricular dysfunction (RVD) is common in patients with heart failure with reduced ejection fraction, and it is associated with poor prognosis.

Biomarkers 40

Biomarkers Heart Failure Heart Transplant Transplant 40

Circulation

OCTOBER 21, 2024

Circulation, Ahead of Print. Transplantation of these cells caused vascular malformations. BACKGROUND:Arteriovenous malformations (AVMs) are characteristic of hereditary hemorrhagic telangiectasia. Loss-of-function mutations in the activin receptorlike kinase 1 (Alk1) are linked to hemorrhagic telangiectasia type 2.METHODS:Endothelial-specific

Hemorrhage 40

Hemorrhage Transplant Ischemia Pulmonary 40

Circulation

FEBRUARY 5, 2025

Circulation, Ahead of Print. BACKGROUND:Although combination antiretroviral therapy has increased life expectancy in people living with HIV, it has led to a marked increase in the prevalence of hypertension, the cause of which is unknown.

Hypertension 45

Hypertension Blood Pressure Transplant Circulation 45

Circulation

NOVEMBER 11, 2024

Circulation, Volume 150, Issue Suppl_1 , Page A4140979-A4140979, November 12, 2024. Background:Lipid metabolic alterations are emerging as significant mechanisms in the prognosis of cardiac remodeling induced by hypertension and could impact the therapies for cardiac fibrosis.

Hypertension 40

Hypertension Transplant Cardiac Function Circulation 40

Circulation

FEBRUARY 15, 2024

Circulation, Ahead of Print. BACKGROUND:Clonal hematopoiesis of indeterminate potential (CHIP), a common age-associated phenomenon, associates with increased risk of both hematological malignancy and cardiovascular disease.

Atrial Fibrillation 45

Atrial Fibrillation Diet Myocardial Infarction Cardiovascular Disease 45

Circulation: Heart Failure

MARCH 8, 2024

Circulation: Heart Failure, Ahead of Print. Centers performing at least 1 heart transplant or left ventricular assist device were classified as ATCs. Patient characteristics, outcomes, and procedural volume were compared among 3 cohorts: admissions to non-ATCs, admissions to ATCs, and transfers to ATCs.

Heart Failure 40

Heart Failure Cardiogenic Shock Outcomes Cardiac Arrest 40

Circulation: Cardiovascular Interventions

NOVEMBER 6, 2023

Circulation: Cardiovascular Interventions, Ahead of Print. Conclusions:Transcatheter palliation with PFR is feasible, safe, and represents an effective strategy for bridging high-risk neonates with congenital heart disease to surgical palliation, complete repair, or transplant while allowing for clinical stabilization and somatic growth.

Congenital Heart Disease 40

Congenital Heart Disease Congenital Heart Disease Pulmonary 40

Circulation

NOVEMBER 11, 2024

Circulation, Volume 150, Issue Suppl_1 , Page A4146624-A4146624, November 12, 2024. Introduction:Ventricular assist devices (VADs) present great promise as both bridge-to-transplant and destination therapies for patients with end-stage heart failure.

Thrombosis 40

Thrombosis Transplant Heart Failure Circulation 40

Circulation

NOVEMBER 11, 2024

Circulation, Volume 150, Issue Suppl_1 , Page A4146466-A4146466, November 12, 2024. Background:Without timely intervention, pressure-overloading left ventricular (poLV) remodeling may become progressive and readily degenerate into heart failure.

Congenital Heart Disease 40

Congenital Heart Disease Heart Failure Pediatrics Transplant 40